Skip to main content
Feb 23, 2022

Vaxart appoints first general counsel

Edward Berg was previously with BioMarin Pharmaceutical

Nasdaq-listed Vaxart has appointed Edward Berg as the biotech company’s first in-house general counsel.

During his legal career Berg has represented Fortune 500 and mid-cap companies in the biotech, pharmaceuticals and life sciences fields. His work has included leading teams of attorneys in commercial and clinical operations, advising on transactions and working with cross-functional teams to ensure compliance with the extensive regulatory framework governing the life sciences industry.

Edward Berg, Vaxart

He joins Vaxart from BioMarin Pharmaceutical, where he has been vice president and deputy general counsel since 2018. During his time with the company, Berg advised on product launches and supported efforts that led to the development of an early pipeline in the competitive gene therapy space. 

Before BioMarin Pharmaceutical, Berg was vice president for legal in the BioPharm division of Sandoz US, a Novartis company. His previous legal roles include deputy general counsel for pharmaceutical operations at Sanofi-Aventis US and Sanofi Pharmaceuticals, and senior corporate counsel for research and development at Bristol-Myers Squibb. He began his career in the healthcare field as a senior attorney/associate counsel for Merck & Co.

Vaxart is a clinical-stage biotech company developing vaccines designed to be administered using tablets that can be stored and shipped without refrigeration and that remove the risk of injuries from needles.

Vaxart CEO Andrei Floroiu says in a statement: ‘Ed has more than 25 years of experience advising biotech and pharma companies, and we are excited to benefit from his acumen as he joins Vaxart as our first in-house general counsel.’

Berg says in an announcement: ‘I am excited to join Vaxart because of its mission to have a transformative impact on global public health. The company’s oral tablet vaccine may increase vaccination rates and has the potential to effectively vaccinate against a number of diseases, which will help improve health for people around the world.’

Ben Maiden

Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...